Drug intelligence / Profile preview

BLD-3051

Development stage: Preclinical
Lead developer: Blade Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

**BLD-3051** is a small molecule calpain inhibitor developed by Blade Therapeutics, Inc. for fibrotic diseases. It has demonstrated promising preclinical efficacy in reducing liver fibrosis, including significant decreases in NAFLD Activity Score (NAS) components such as inflammation and steatosis, as well as liver hydroxyproline levels, a marker of collagen deposition. The program targets calpain proteases, which play a key role in fibrotic pathologies, with initial focus on pulmonary fibrosis and expansion into liver fibrosis models.[1][4]

Targets

CAPN9 (Calpain-9)CAPN (Schistosoma calpain large subunit family)

Beyond the preview

Go deeper on BLD-3051.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLD-3051.

Explore the full profile